Catheter

Global Urinary Tract Infection (UTI) Treatment Market is expected to Reach US$ 13,617.4 million by 2034, rising at a 1.9% CAGR- FMI Study

Retrieved on: 
Monday, January 22, 2024
Patient, Catheter, Research, Bladder cancer, UTI, Developed country, Risk, Urinary tract infection, Kidney, System, Cardiac catheterization, Drainage, Infection, FMI, Diagnosis, Prevalence, Medical imaging

NEWARK, Del., Jan. 22, 2024 /PRNewswire/ -- The Urinary Tract Infection (UTI) Treatment Market is estimated to be worth US$   11,244.0 million in 2024 and is projected to be valued at US$ 13,617.4 million in 2034. Between 2024 and 2034, the industry is expected to register a growth rate of 1.9%.

Key Points: 
  • Future Market Insights, Inc. (FMI) predicts a robust expansion of the urinary tract infection (UTI) treatment market, propelled by increasing infection rates, catheter use, and advancements in diagnosis and care.
  • Dive deeper into the intricate dynamics of this burgeoning market and uncover compelling stakeholder opportunities in our comprehensive FMI report.
  • NEWARK, Del., Jan. 22, 2024 /PRNewswire/ -- The Urinary Tract Infection (UTI) Treatment Market is estimated to be worth US$   11,244.0 million in 2024 and is projected to be valued at US$ 13,617.4 million in 2034.
  • Individuals using urinary catheters face an elevated risk of developing complicated urinary tract infections, driving the demand for UTI treatment .

Intravascular Ultrasound (IVUS) Global Strategic Analysis Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Radiology, Health, Cardiology, Medical Devices, Hospital, Growth, Catheter, Coronary artery disease, Percutaneous coronary intervention, IVUS, COVID-19, Medical ultrasound, PCI, CAD, Intravascular ultrasound, Medical imaging

The "Intravascular Ultrasound (IVUS) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intravascular Ultrasound (IVUS) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of Medical Ultrasound, with a specific focus on Intravascular Ultrasound (IVUS) and its applications in the medical field.
  • It begins with a general introduction to medical ultrasound and highlights the advantages of ultrasound as compared to other imaging modalities.
  • The report discusses the indications and techniques of Intravascular Ultrasound, providing a comprehensive understanding of its use in medical procedures.

Global Cardiac Ablation Devices Market Analysis and Forecasts, 2017-2022 and 2023-2027 with 2022 as the Base Year Featuring Arga Medtech, Boston Scientific, Abbott, Johnson & Johnson, and Medtronic - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 9, 2024
Health, Medical Devices, Cardiology, Arrhythmia, RF, Catheter, Patient, Traction, Insurance, Cryoablation, AI, Growth, Safety, COVID-19, Pharmacotherapy, Robotics, Prevalence, Medical device

This study analyzes the global cardiac ablation device market, including the entire market landscape by end-users, application types, device types, and market share percentage by market players.

Key Points: 
  • This study analyzes the global cardiac ablation device market, including the entire market landscape by end-users, application types, device types, and market share percentage by market players.
  • The study provides specific market growth opportunities focusing on disruptive innovations, new unaddressed markets, increasing prevalence of cardiac arrhythmia, and others.
  • Rising incidents of cardiac arrhythmia and the increasing demand for minimally invasive procedures boost the cardiac ablation (CA) market growth.
  • With the lessening of pandemic restrictions from 2022, the worldwide backlog of CA procedures surged the CA device market growth.

Israeli Humanitarian Organization Celebrates Saving Its 7000th Child Amidst Wartime Crisis

Retrieved on: 
Thursday, January 11, 2024
Family, Wolfson Medical Center, Heart, Female, Catheter, Friends, Echocardiography, TEL, Child, Save a Child's Heart, Hospital, Save, Ventricular septal defect, Cardiology, Nursing

TEL AVIV, Israel, Jan. 11, 2024 /PRNewswire/ -- Save a Child's Heart (SACH), an Israeli humanitarian organization, marked a major milestone when it treated Kelvin, a 10-year-old from Kenya. Kelvin became Save a Child's Heart's 7,000th child saved by the volunteer Israeli doctors of SACH. 

Key Points: 
  • Save a Child's Heart, an international Israeli humanitarian organization, treated its 7,000th child in Israel, a 10-year-old boy from Kenya, while providing urgent medical care to casualties of tragic attacks in Israel.
  • TEL AVIV, Israel, Jan. 11, 2024 /PRNewswire/ -- Save a Child's Heart (SACH), an Israeli humanitarian organization, marked a major milestone when it treated Kelvin, a 10-year-old from Kenya.
  • Kelvin became Save a Child's Heart's 7,000th child saved by the volunteer Israeli doctors of SACH.
  • Kelvin said he was excited and proud to be the 7,000th child treated: "Being the 7,000th kid helped by Save a Child's Heart felt really good.

Global Airway Management Devices Market Report 2023-2033: Rising Demand for Advanced Airway Management Devices Driven by Surgical Surges and Chronic Illnesses

Retrieved on: 
Tuesday, January 9, 2024
Anesthesia, Growth, Competitive landscape, Airway management, Asthma, Catheter, Chronic obstructive pulmonary disease, Prevalence, COPD, Airline

The escalating demand for airway management devices is primarily propelled by the increasing prevalence of respiratory conditions, particularly Chronic Obstructive Pulmonary Disease (COPD).

Key Points: 
  • The escalating demand for airway management devices is primarily propelled by the increasing prevalence of respiratory conditions, particularly Chronic Obstructive Pulmonary Disease (COPD).
  • Geographically, North America is poised to emerge as a major contributor to the growth of the airway management devices market.
  • What are the major market drivers, challenges and opportunities in the global airway management devices market and their case studies?
  • What is the market share of the leading segments and sub-segments of the global airway management devices market?

Clarius Adds AI-Driven Automatic Bladder Volume Measurements to its Wireless Handheld Ultrasound Scanners Designed for Acute Care, Urology, and Nursing

Retrieved on: 
Tuesday, January 9, 2024
Clarius, Patient, Catheter, Cauda equina syndrome, Literature, Urine, Rehabilitation, Education minister, Abdominal pain, Ultrasound, Urinary retention, Nursing, Food, Nursing home, UI, FDA, Hydronephrosis, PMID, Diagnosis, Urinary tract obstruction, Physician

VANCOUVER, BC, Jan. 9, 2024 /PRNewswire/ -- Clarius Mobile Health, a global leader in wireless ultrasound solutions, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Clarius Bladder AI, a non-invasive tool that automatically measures bladder volume in seconds. It's available now in the United States with the Clarius PAL HD3, Clarius PA HD3 and the Clarius C3 HD3 wireless handheld ultrasound scanners.

Key Points: 
  • It's available now in the United States with the Clarius PAL HD3 , Clarius PA HD3 and the Clarius C3 HD3 wireless handheld ultrasound scanners.
  • The latest addition to the Clarius AI portfolio , Clarius Bladder AI accurately measures bladder volume and provides real-time feedback to clinicians.
  • Clarius Bladder AI is included among other advanced software features that are available with the Advanced Primary / Critical Care Package , included with Clarius Membership .
  • Current Clarius members with eligible scanners will be able to use the new application on their Clarius scanners today.

Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met

Retrieved on: 
Thursday, December 28, 2023
FDA, Catheter, GLP, IDE

BRAINTREE, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.

Key Points: 
  • BRAINTREE, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.
  • As previously announced on December 7, 2023, the study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations.
  • “I am very pleased with the positive outcomes of the histopathology report and the completion of the GLP study,” said Juan Diaz Cartelle, Chief Medical Officer.
  • “We expect to submit our IDE application to the FDA soon and commence our pivotal human clinical trial, completing our transition to a clinically stage company.”

Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study

Retrieved on: 
Thursday, December 7, 2023
FDA, Catheter, GLP, IDE, Trial of the century, Pharmaceutical industry

BRAINTREE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.

Key Points: 
  • The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study.
  • The study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations.
  • “I am very pleased with the positive outcomes of the histopathology report and the completion of the GLP study,” said Juan Diaz Cartelle, Chief Medical Officer.
  • “We expect to submit our IDE application to the FDA soon and commence our pivotal human clinical study, completing our transition to a clinically stage company.”

Teleflex Awarded Peripheral Access Agreement with Premier, Inc.

Retrieved on: 
Tuesday, December 5, 2023
Peripheral, PICC, TFX, Premier, VPS, CLABSI, Hospital, Catheter, Navigation, Patient, Teleflex, Fungal infection, Medical imaging

WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded the Peripheral Access purchasing agreement with Premier, Inc.

Key Points: 
  • WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded the Peripheral Access purchasing agreement with Premier, Inc.
  • Effective December 1st, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex’s Peripheral Access products.
  • Premier has awarded Teleflex a national multi-source agreement for Peripherally Inserted Central Catheters (PICCs), PICC navigation equipment, and Midlines.
  • “Teleflex strives to deliver vascular access products that are designed to benefit both clinicians and patients, while helping to protect against vascular access related complications1-7,” said Lisa Kudlacz, President and General Manager, Teleflex Vascular.

Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

Retrieved on: 
Monday, November 20, 2023
MTD, Neurology, Neoplasm, PSTV, Index, IND, University of Texas System, Catheter, SNO, EBRT, Neuro-oncology, Plus, Neuro, Decompression (diving), MD, Doctor of Philosophy, Therapy, Clinical trial, Standard of care, CED, Society, Annual general meeting, Bevacizumab, MFD, Plus Therapeutics, NIH, Patient, University, Safety, Phase II, SOC, Radiation, KOL, Pharmaceutical industry

The Company is hosting a virtual key opinion leader (KOL) webinar to discuss the data today at 10:00 am ET.

Key Points: 
  • The Company is hosting a virtual key opinion leader (KOL) webinar to discuss the data today at 10:00 am ET.
  • Rhenium (186Re) obisbemeda continues to be generally safe and well tolerated, consistent with data accumulated in the Phase 1 trial.
  • Plus Therapeutics is hosting a virtual KOL event today, November 20, 2023 at 10:00 am ET to discuss the data presented at SNO.
  • A replay of the event will be available on Investor Relations section of the Plus Therapeutics website after the event.